Cardiosonic Closes On $6.1M Series B

Cardiosonic Inc., a company developing technology in the field of Renal Denervation for the treatment of Hypertension, has closed on $6.1 million in Series B financing. An undisclosed “strategic investor” led the round. Cardiosonic is based in Tel Aviv, Israel.

North AmericaUSBriefs